The Science of DHT and Androgenetic Alopecia
Last reviewed: March 21, 2026, 7:02 a.m.
Dihydrotestosterone (DHT) is a potent androgen hormone that plays a central role in the development of androgenetic alopecia, the most common form of hair loss worldwide. DHT is produced when the enzyme 5-alpha reductase converts testosterone into its more active form. While DHT is essential during fetal development for the formation of male external genitalia, its effects on genetically susceptible hair follicles in adulthood drive the progressive miniaturization that characterizes pattern hair loss.
In susceptible individuals, DHT binds to androgen receptors in the dermal papilla cells of hair follicles, triggering a cascade of events that shortens the anagen (growth) phase and prolongs the telogen (resting) phase. Over successive hair cycles, terminal hairs are gradually replaced by finer, shorter vellus hairs until the follicle eventually ceases to produce visible hair. Importantly, not all hair follicles are equally sensitive to DHT, which is why pattern hair loss follows characteristic distributions, affecting the frontal hairline and crown while typically sparing the sides and back of the scalp.
Finasteride, a 5-alpha reductase type II inhibitor, is one of only two FDA-approved medications for male pattern hair loss. At a dose of 1 mg daily, research shows it may reduce scalp DHT levels by approximately 64% and serum DHT by about 68%. Clinical trials have demonstrated that finasteride may help slow hair loss progression and support regrowth in a significant proportion of men, with peak results typically observed after 1 to 2 years of consistent use. Dutasteride, which inhibits both type I and type II 5-alpha reductase, produces greater DHT reduction but is not FDA-approved for hair loss and is used off-label.
For those seeking natural alternatives, several botanical compounds have been studied for their potential to influence the DHT pathway. Saw palmetto (Serenoa repens) has received the most research attention, with a 2020 meta-analysis in Complementary Therapies in Medicine finding that it may support improvements in hair density in 60% of treated patients, though the effect size was smaller than that of finasteride. Pumpkin seed oil showed promising results in a 2014 randomized, double-blind, placebo-controlled trial, where participants receiving 400 mg daily showed a 40% increase in hair count after 24 weeks. Green tea extract, containing the catechin EGCG, has demonstrated 5-alpha reductase inhibition in laboratory studies, though human clinical data remains limited.
It is important to note that while DHT plays a pivotal role in androgenetic alopecia, the condition is multifactorial, involving genetics, hormonal influences, inflammation, and microvascular changes. A comprehensive approach that addresses multiple pathways may yield better results than targeting DHT alone. Any anti-androgenic supplement or medication should be discussed with a healthcare provider, particularly for women of childbearing age, as DHT-modifying compounds may pose risks during pregnancy.
In susceptible individuals, DHT binds to androgen receptors in the dermal papilla cells of hair follicles, triggering a cascade of events that shortens the anagen (growth) phase and prolongs the telogen (resting) phase. Over successive hair cycles, terminal hairs are gradually replaced by finer, shorter vellus hairs until the follicle eventually ceases to produce visible hair. Importantly, not all hair follicles are equally sensitive to DHT, which is why pattern hair loss follows characteristic distributions, affecting the frontal hairline and crown while typically sparing the sides and back of the scalp.
Finasteride, a 5-alpha reductase type II inhibitor, is one of only two FDA-approved medications for male pattern hair loss. At a dose of 1 mg daily, research shows it may reduce scalp DHT levels by approximately 64% and serum DHT by about 68%. Clinical trials have demonstrated that finasteride may help slow hair loss progression and support regrowth in a significant proportion of men, with peak results typically observed after 1 to 2 years of consistent use. Dutasteride, which inhibits both type I and type II 5-alpha reductase, produces greater DHT reduction but is not FDA-approved for hair loss and is used off-label.
For those seeking natural alternatives, several botanical compounds have been studied for their potential to influence the DHT pathway. Saw palmetto (Serenoa repens) has received the most research attention, with a 2020 meta-analysis in Complementary Therapies in Medicine finding that it may support improvements in hair density in 60% of treated patients, though the effect size was smaller than that of finasteride. Pumpkin seed oil showed promising results in a 2014 randomized, double-blind, placebo-controlled trial, where participants receiving 400 mg daily showed a 40% increase in hair count after 24 weeks. Green tea extract, containing the catechin EGCG, has demonstrated 5-alpha reductase inhibition in laboratory studies, though human clinical data remains limited.
It is important to note that while DHT plays a pivotal role in androgenetic alopecia, the condition is multifactorial, involving genetics, hormonal influences, inflammation, and microvascular changes. A comprehensive approach that addresses multiple pathways may yield better results than targeting DHT alone. Any anti-androgenic supplement or medication should be discussed with a healthcare provider, particularly for women of childbearing age, as DHT-modifying compounds may pose risks during pregnancy.